Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

BACKGROUND: The ABL kinase inhibitor imatinib is highly effective in treating most, but not all, patients with chronic myeloid leukemia (CML). This is because residual CML cells are generally present in the bone marrow microenvironment and are refractory to imatinib. Hematopoietic cytokine receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Seiichi, Tauchi, Tetsuzo, Katagiri, Seiichiro, Tanaka, Yuko, Ohyashiki, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012544/
https://www.ncbi.nlm.nih.gov/pubmed/24775308
http://dx.doi.org/10.1186/1756-8722-7-37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012544/
https://www.ncbi.nlm.nih.gov/pubmed/24775308
http://dx.doi.org/10.1186/1756-8722-7-37

Ejemplares similares